Corey Clay , MD, PhD, CSTP Graduate 2016

MD/PhD: Ohio State University College of Medicine

Doctor of Philosophy : Ohio State University

Master of Science : University of Cincinnati

BS: University of Notre Dame (Pre-professional Sciences)

I studied roles of the complement system in the pathogenesis of F. tularensis. This deadly bacterium is given the highest research priority classification by the CDC as a Category A Select Agent. Most successful human pathogens have evolved molecular mechanisms to subvert, inactivate, or exploit proteins of the complement system. Working in biosafety level 2 and 3 laboratories, my dissertation project was fourfold: 1) to identify complement components activated by specific bacterial surface moieties expressed by F. tularensis and to characterize the relative involvement of subsequent pathways within the overall complement system; 2) to identify resistance mechanisms to the bactericidal effects of complement; 3) to elucidate the functional activities of primary human macrophages in response to complement-mediated phagocytosis of F. tularensis; and 4) to study human bronchoalveolar lavage fluid in order to identify potential modulatory effects of distinct innate immune molecules present within the lung.
 
I studied environmentally pervasive halogenated aromatic hydrocarbons and associated toxic mechanisms involving the metabolic generation of reactive oxygen species and the formation of genotoxic DNA-binding metabolites. In vivo model systems included genetically modified mice containing targeted cytochrome P450 system gene deletions, "humanized mice" containing human gene insertions, and various secondary cell lines. In vitro model systems were developed by isolating subcellular fractions both from cell lines and from excised murine organs containing oxidoreductase enzyme systems that are associated with the intracellular endoplasmic reticulum and mitochondria. My thesis work focused on relative reactive oxygen generation via uncoupled redox reactions involving the environmental toxins TCDD and polyhalogenated biphenyls and specific inducible and constitutive cytochrome P450 enzymes including CYP1A1, CYP1A2, and CYP2E1.
         
 

Published Abstracts

Khodoun, M.V., Kucuk, Z.Y., Strait, R.T., Krishnamurthy, D., Janek, K., Clay, C.D., Morris, S.C. and Finkelman, F.D. (2013. ) Rapid desensitization of mice with anti-FcγRIIb/FcγRIII mAb safely prevents IgG-mediated anaphylaxis .[Abstract]Allergy and Clinical Immunology, 132(6) ,1375

Mohapatra, N.P., Soni, S., Rajaram, M.V., Dang, P.M.C., Reilly, T.J., El-Benna, J., Clay, C.D., Schlesinger, L.S. and Gunn, J.S. (2010. ) Francisella acid phosphatases inactivate the NADPH oxidase in human phagocytes .[Abstract]The Journal of Immunology, 184(9) ,5141

Cremer, T.J., Ravneberg, D.H., Clay, C.D., Piper-Hunter, M.G., Marsh, C.B., Elton, T.S., Gunn, J.S., Amer, A., Kanneganti, T.D., Schlesinger, L.S. and Butchar, J.P. (2009. ) MiR-155 induction by F. novicida but not the virulent F. tularensis results in SHIP down-regulation and enhanced pro-inflammatory cytokine response .[Abstract]PloS one, 4(12) ,8508

OSU Presidential Doctoral Fellowship

2008 -2008 OSU Presidential Doctoral Fellowship highest scholarly achievement awarded by the OSU Graduate School

2005 -2005 OSU University Doctoral Fellowship

2004 -2010 Letters of Commendation in MY1 core curriculum (2004) and MY3 core surgery clerkship (2010)

2009 -2009 Honors in 2 MY4 individual studies electives (2009) MD/PhD Leadership and Academic Achievement Scholarship (2007).

2009 -2009 Honors in 2 MY4 individual studies electives

2007 -2007 MD/PhD Leadership and Academic Achievement Scholarship

Phone: 513-558-2590